| Literature DB >> 32316923 |
Jia Bainga Kangbai1,2, Christian Heumann3, Michael Hoelscher4,5, Foday Sahr6,7, Guenter Froeschl4,5.
Abstract
BACKGROUND: The 2013-2016 West Africa Ebola Virus Disease (EVD) outbreak recorded the highest incidence and mortality since the discovery of the virus in Zaire in 1976; with more than 28,000 probable and confirmed EVD cases and 11,000 deaths. Studies relating to previous outbreaks usually involved small sample sizes. In this study we are set to identify those sociodemographic and clinical features that predict in-facility mortality among EVD patients using a large sample size.Entities:
Keywords: Case fatality rate; Ebola; Ebola treatment center; Sierra Leone; Treatment outcome
Mesh:
Year: 2020 PMID: 32316923 PMCID: PMC7171792 DOI: 10.1186/s12879-020-04994-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Distribution of EVD patients treated between the period of 2014–2015 at The 34 Military Hospital and The Police Training School ETCs during the 2013–2016 West African Ebola outbreak according to their age groups and respective CFRs
Fig. 2a. Distribution of the frequency of clinical symptoms of EVD patients treated between the period of 2014–2015 at The 34 Military Hospital and The Police Training School ETCs during the 2013–2016 West African Ebola outbreak and their CFRs. b. Distribution of the Stage of EVD Infection of EVD patients treated between the period of 2014–2015 at The 34 Military Hospital and The Police Training School ETCs during the 2013–2016 West African Ebola outbreak and their CFRs
Fig. 3Distribution of EVD patients treated between the period of 2014–2015 at The 34 Military Hospital and The Police Training School ETCs during the 2013–2016 West African Ebola outbreak according to CFR and sex
The Adjusted Multivariate Analysis of In-facility Case Fatality Rates of EVD patients treated between the period of 2014–2015 at The 34 Military Hospital and The Police Training School ETCs during the 2013–2016 West African Ebola outbreak
| Patient symptoms | Adjusted OR | 95% CI | |
|---|---|---|---|
Sex – Male Reference = Female | 1.50 | 0.95–2.26 | 0.09 |
| Reference age group = 15 to < 25 years | |||
| 25 to < 35 years | 1.09 | 0.58–2.38 | 0.80 |
| 35 to < 45 years | 1.84 | 0.98–3.49 | 0.06 |
| 45 to < 55 years | 1.64 | 0.70–3.90 | 0.26 |
| 55 to < 65 years | 2.81 | 0.91–8.27 | 0.07 |
| 65 years and above | 12.50 | 2.32–80.74 | 0.005 |
| Fever | 1.46 | 0.87–7.98 | 0.16 |
| Cough | 1.79 | 1.12–2.86 | 0.02 |
| Vomiting | 3.21 | 1.88–5.58 | < 0.00001 |
| Diarrhoea | 4.01 | 1.85–9.40 | 0.0008 |
| Fatigue | 2.64 | 1.39–5.29 | < 0.00001 |
| Dysphagia | 7.16 | 4.40–11.80 | < 0.00001 |
| Conjunctival injection | 3.45 | 2.02–5.94 | < 0.00001 |
| Dyspnea | 3.63 | 2.07–6.46 | < 0.00001 |
aAdjusted OR is Adjusted odds ratio
Fig. 4ROC Curve on EVD Treatment Survival Determinants and Treatment Outcome
Matrix of actual and predicted treatment of outcome for EVD patients
| EVD Patients predicted status | EVD treatment survivors | EVD treatment fatalities | Total |
|---|---|---|---|
| Predicted EVD survivors | 690 | 51 | 741 |
| Predicted EVD fatalities | 0 | 197 | 197 |
| Total | 690 | 248 | 938 |